Hikma Pharmaceuticals (OTCMKTS:HKMPF) Sets New 52-Week High – Should You Buy?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) reached a new 52-week high on Wednesday. The company traded as high as $23.5850 and last traded at $23.5850, with a volume of 200 shares traded. The stock had previously closed at $23.41.

Analyst Ratings Changes

Several brokerages recently issued reports on HKMPF. Barclays raised Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 12th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.

Hikma Pharmaceuticals Price Performance

The company has a fifty day moving average price of $21.80 and a 200-day moving average price of $20.21.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad range of generic, branded and specialty medicines. Its portfolio includes injectable medicines, oral solid-dose products, inhalation products and other treatments used in hospitals, pharmacies and community-care settings.

The company operates through three principal businesses: Injectables, Generics and Branded Medicines. Hikma supplies injectable products to hospitals and healthcare providers, offers generic medicines primarily in the United States, and markets branded and licensed medicines across the Middle East and North Africa.